Star Therapeutics Raises $200M in Private Financing

Star Therapeutics, a San Francisco-based biotechnology company developing treatments for diseases with unmet medical needs, has raised $200 million in a private financing round.

The round was co-led by OrbiMed and Janus Henderson Investors, with participation from Agent Capital, Catalio Capital Management, Cormorant Asset Management, New Leaf Venture Partners, NYBC Ventures, RA Capital Management, Redmile, Sofinnova Investments, Soleus Capital, and other investors.

The company will use the funds to support its therapy pipeline and advance its current preclinical programmes into clinical development.

What is Star Therapeutics?

Star Therapeutics is a biotechnology company focused on discovering and developing treatments for diseases with significant unmet medical needs. Its work centres on antibody-based therapies designed to address conditions for which existing treatment options may be limited.

Read More:Albert Receives Investment From Applied Ventures

The company develops therapies through its research programmes and related businesses. Its team has worked on treatments across several stages of development, from early research to late-stage clinical trials and commercialisation.

Star Therapeutics focuses on advancing new therapies that could provide treatment options for patients with serious diseases.

How Much Funding Has Star Therapeutics Raised?

Star Therapeutics has raised $200 million in its latest private financing round. The company did not disclose its total funding to date or details of previous rounds in the announcement.

Who Invested in Star Therapeutics’ Private Financing?

The $200 million round was co-led by OrbiMed, and Janus Henderson Investors.

Other participating investors include:

• Agent Capital
• Catalio Capital Management
• Cormorant Asset Management
• New Leaf Venture Partners
• NYBC Ventures
• RA Capital Management
• Redmile
• Sofinnova Investments
• Soleus Capital
• Other investors

Why the Funding Matters

Star Therapeutics will use the new capital to support its therapy pipeline and move its current preclinical programmes into clinical development.

The funding will help the company continue its work on treatments for diseases with unmet medical needs. Advancing preclinical programmes into clinical trials is an important step in evaluating potential therapies for safety and effectiveness in humans.

Who founded Star Therapeutics?

Star Therapeutics was founded by Adam Rosenthal. The company is headquartered in San Francisco, California. The announcement did not specify the company's founding year.

The team behind Star Therapeutics has contributed to the development of four first-in-class antibody therapies, including Enjaymo, the first approved treatment for cold agglutinin disease, and three other therapies that have reached Phase 3 development.

“Our mission is to develop best-in-disease therapies at scale for the millions of patients with diseases of significant unmet need,” said Adam Rosenthal, Ph.D., founder and chief executive officer of Star Therapeutics. “This financing marks the next phase for Star, building on our team’s track record of discovering and developing novel medicines.

“Star stood out to us because of the strength of its team and its proven ability to invent and develop innovative therapies,” said Vish Sridharan, M.D., assistant portfolio manager and research analyst at Janus Henderson Investors, who is joining as a board observer for Star Therapeutics.

Market and Business Growth

Star Therapeutics has built a track record in drug development through its team’s work across multiple companies. Team members have contributed to four successful acquisitions involving Vega Therapeutics, DICE Therapeutics, True North Therapeutics, and iPierian.

In July 2026, Incyte completed the acquisition of Stars wholly owned subsidiary Vega Therapeutics in a transaction valued at up to $2 billion.

What Happens Next?

Star Therapeutics plans to use the $200 million financing to support its existing therapy pipeline and advance preclinical programmes into clinical trials.

The company will continue focusing on the discovery and development of treatments for diseases with significant unmet medical needs.

Read More:PreScalar Raises $7M in Seed Funding Led by Dynamo Ventures